Accéder au contenu
Merck

ABCs of Neonatal Cardiac Anesthesia.

Artificial organs (2013-01-12)
Chris Chin
RÉSUMÉ

Congenital heart disease (CHD) is relatively common and there are treatment options for virtually every form of CHD. With good care, the majority of babies can survive to adulthood; however, CHD remains a significant cause of death in infancy and neonates are especially vulnerable. In order to manage these patients, a clear understanding of the underlying pathophysiology and the planned surgical procedure is important. However, attention to detail and meticulous care are equally important, and, in addition, there are several management strategies that may standardize practice and can improve outcome.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
sulfate de magnésium, anhydrous, ReagentPlus®, ≥99.5%
Sigma-Aldrich
Sulfate de magnésium heptahydraté, ACS reagent, ≥98%
Sigma-Aldrich
Sulfate de magnésium heptahydraté, ReagentPlus®, ≥99.0%
Sigma-Aldrich
sulfate de magnésium, BioReagent, suitable for cell culture, suitable for insect cell culture
Sigma-Aldrich
Sulfate de magnésium heptahydraté, BioReagent, for molecular biology, suitable for plant cell culture, ≥99.0%
Sigma-Aldrich
sulfate de magnésium, puriss. p.a., drying agent, anhydrous, ≥98.0% (KT), powder (very fine)
Sigma-Aldrich
Magnesium sulfate solution, for molecular biology, 1.00 M±0.04 M
Sigma-Aldrich
Sulfate de magnésium heptahydraté, BioUltra, ≥99.5% (KT)
Sigma-Aldrich
Magnesium sulfate solution, BioUltra, for molecular biology
Sigma-Aldrich
sulfate de magnésium, ≥99.99% trace metals basis
Sigma-Aldrich
Sulfate de magnésium heptahydraté, BioXtra, ≥99.0%